Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease

CNS and Neurological Disorders - Drug Targets

Volumn 9, Issue 2, 2010, Pages 140-148

  Cole, Greg M ^a,b,c   Frautschy, Sally A ^a,b,c  

^a Greater Los Angeles Healthcare System   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Curcumin; Cyclooxygenases; Docosahexaenoic acid; Non steroidal anti inflammatory drugs

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; FLAVONOID; FLURBIPROFEN; GAMMA SECRETASE; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PLACEBO; PROSTAGLANDIN E2; TRIFLUSAL;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; DEMENTIA; DRUG EFFICACY; DRUG MECHANISM; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INNATE IMMUNITY; INTERMETHOD COMPARISON; LONG TERM POTENTIATION; MILD COGNITIVE IMPAIRMENT; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PHARMACOGENOMICS; PRIMARY PREVENTION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 77949892092     PISSN: 18715273     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152710791011991     Document Type: Review

References (98)

1. Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.E.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffin, W.S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; O'Banion, M.K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F.L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T. Inflammation and Alzheimer's disease. Neurobiol. Aging, 2000, 21, 383-421.
2. McGeer, P.L.; McGeer, E.G. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging, 2007, 28, 639-647.
3. Aisen, P.S.; Thal, L.J.; Ferris, S.H.; Assaid, C.; Nessly, M.L.; Giuliani, M.J.; Lines, C.R.; Norman, B.A.; Potter, W.Z. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr. Alzheimer Res., 2008, 5, 73-82.
4. Szekely, C.A.; Thorne, J.E.; Zandi, P.P.; Ek, M.; Messias, E.; Breitner, J.C.; Goodman, S.N. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology, 2004, 23, 159-169.
5. Vlad, S.C.; Miller, D.R.; Kowall, N.W.; Felson, D.T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology, 2008, 70, 1672-1677.
6. Frautschy, S.A.; Yang, F.; Irizarry, M.; Hyman, B.; Saido, T.C.; Hsiao, K.; Cole, G.M. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol., 1998, 152, 307-317.
7. Lim, G.P.; Yang, F.; Chu, T.; Chen, P.; Beech, W.; Teter, B.; Tran, T.; Ubeda, O.; Ashe, K.H.; Frautschy, S.A.; Cole, G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's Disease. J. Neurosci., 2000, 20(15), 5709-5714.
8. Yan, Q.; Zhang, J.; Liu, H.; Babu-Khan, S.; Vassar, R.; Biere, A.L.; Citron, M.; Landreth, G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci., 2003, 23, 7504-7509.
9. Eriksen, J.L.; Sagi, S.A.; Smith, T.E.; Weggen, S.; Das, P.; McLendon, D.C.; Ozols, V.V.; Jessing, K.W.; Zavitz, K.H.; Koo, E.H.; Golde, T.E. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest., 2003, 112, 440-449.
10. Weggen, S.; Eriksen, J.L.; Das, P.; Sagi S.A.; Wang, R.; Pietrzik, C.U.; Findlay, K.A.; Smith, T.E.; Murphy, M.P.; Bulter, T.; Kang, D.E.; Marquez-Sterling, N.; Golde, T.E.; Koo, E.H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 2001, 414, 212-216.
11. Szekely, C.A.; Green, R.C.; Breitner, J.C.; Ostbye, T.; Beiser, A.S.; Corrada, M.M.; Dodge, H.H.; Ganguli, M.; Kawas, C.H.; Kuller, L.H.; Psaty, B.M.; Resnick, S.M.; Wolf, P.A.; Zonderman, A.B.; Welsh-Bohmer, K.A.; Zandi, P.P. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology, 2008, 70, 2291-2298.
12. Morihara, T.; Teter, B.; Yang, F.; Lim, G.P.; Boudinot, S.; Boudinot, F.D.; Frautschy, S.A.; Cole, G.M. Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models. Neuropsychopharmacology, 2005, 30, 1111-1120.
13. Lim, G.P.; Yang, F.; Chu, T.; Gahtan, E.; Ubeda, O.; Beech, W.; Overmier, J.B.; Hsiao, A.K.; Frautschy, S.A.; Cole, G.M. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging, 2001, 22, 983-991.
14. Jantzen, P.T.; Connor, K.E.; DiCarlo, G.; Wenk, G.L.; Wallace, J.L.; Rojiani, A.M.; Coppola, D.; Morgan, D.; Gordon, M.N. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci., 2002, 22, 2246-2254.
15. Quinn, J.; Montine, T.; Morrow, J.; Woodward, W.R.; Kulhanek, D.; Eckenstein, F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J. Neuroimmunol., 2003, 137, 32-41.
16. Heneka, M.T.; Sastre, M.; Dumitrescu-Ozimek, L.; Hanke, A.; Dewachter, I.; Kuiperi, C.; O'Banion, K.; Klockgether, T.; Van Leuven, F.; Landreth, G.E. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain, 2005, 128, 1442-1453.
17. Lanz, T.A.; Fici, G.J.; Merchant, K.M. Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J. Pharmacol. Exp. Ther., 2005, 312, 399-406.
18. Kukar, T.; Prescott, S.; Eriksen, J.L.; Holloway, V.; Murphy, M.P.; Koo, E.H.; Golde, T.E.; Nicolle, M.M. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci., 2007, 8, 54.
19. Kotilinek, L.A.; Westerman, M.A.; Wang, Q.; Panizzon, K.; Lim, G.P.; Simonyi, A.; Lesne, S.; Falinska, A.; Younkin, L.H.; Younkin, S.G.; Rowan, M.; Cleary, J.; Wallis, R.A.; Sun, G.Y.; Cole, G.; Frautschy, S.; Anwyl, R.; Ashe, K.H. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain, 2008, 131, 651-664.
20. McKee, A.C.; Carreras, I.; Hossain, L.; Ryu, H.; Klein, W.L.; Oddo, S.; LaFerla, F.M.; Jenkins, B.G.; Kowall, N.W.; Dedeoglu, A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res., 2008, 1207, 225-236.
21. Choi, J.K.; Jenkins, B.G.; Carreras, I.; Kaymakcalan, S.; Cormier, K.; Kowall, N.W.; Dedeoglu, A. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp. Neurol., 2009, in press.
22. Coma, M.; Serenó, L.; Da Rocha-Souto, B.; Scotton, T.C.; Espana, J.; Sánchez, M.B.; Rodríguez, M.; Agulló, J.; Guardia-Laguarta, C.; Garcia-Alloza, M.; Agulló, J.; Guardia-Laguarta, C.; Garcia-Alloza, M.; Borrelli, L.A.; Clarimón, J.; Lleó, A.; Bacskai, B.J.; Saura, C.A.; Hyman, B.T.; Gómez-Isla, T. Triflusal reduces densecore plaque load, associated axonal alterations and Inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis., 2010, in press.
23. Martin, B.K.; Szekely, C.; Brandt, J.; Piantadosi, S.; Breitner, J.C.; Craft, S.; Evans, D.; Green, R.; Mullan, M. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol., 2008, 65, 896-905.
24. Streit, W.J.; Braak, H.; Xue, Q.S.; Bechmann, I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol., 2009, 118, 475-485.
25. Walker, D.G.; Dalsing-Hernandez, J.E.; Campbell, N.A.; Lue, L.F. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp. Neurol., 2009, 215, 5-19.
26. Chakrabarty, P.; Jansen-West, K.; Beccard, A.; Ceballos-Diaz, C.; Levites, Y.; Verbeeck, C.; Zubair, A.C.; Dickson, D.; Golde, T.E.; Das, P. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J., 2009, 24, 548-559.
27. Rall, J.M.; Mach, S.A.; Dash, P.K. Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuates memory acquisition in rats. Brain Res., 2003, 968, 273-276.
28. Small, G.W.; Siddarth, P.; Silverman, D.H.; Ercoli, L.M.; Miller, K.J.; Lavretsky, H.; Bookheimer, S.Y.; Huang, S.C.; Barrio, J.R.; Phelps, M.E. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. Am. J. Geriatr. Psychiatry, 2008, 16, 999-1009.
29. Gomez-Isla, T.; Blesa, R.; Boada, M.; Clarimon, J.; Del Ser, T.; Domenech, G.; Ferro, J.M.; Gomez-Anson, B.; Manubens, J.M.; Martinez-Lage, J.M.; Martínez-Lage, J.M.; Muñoz, D.; Peña-Casanova, J.; Torres, F.; TRIMCI Study Group. A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis. Assoc. Disord., 2008, 22, 21-29.
30. Laino, C. In follow-up analysis of clinical trial, NSAIDs seem to preserve cognitive function in patients wtih healthy brains. Neurol. Today, 2009, 9, 21-22.
31. Palop, J.J.; Chin, J.; Roberson, E.D.; Wang, J.; Thwin, M.T.; Bien-Ly, N.; Yoo, J.; Ho, K.O.; Yu, G.Q.; Kreitzer, A.; Finkbeiner, S.; Noebels, J.L.; Mucke, L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron, 2007, 55, 697-711.
32. Kelley, K.A.; Ho, L.; Winger, D.; Freire-Moar, J.; Borelli, C.B.; Aisen, P.S.; Pasinetti, G.M. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am. J. Pathol., 1999, 155, 995-1004.
33. Hoozemans, J.J.; Rozemuller, J.M.; van Haastert, E.S.; Veerhuis, R.; Eikelenboom, P. Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr. Pharm. Des., 2008, 14, 1419-1427.
34. Lukiw, W.J.; Bazan, N.G. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J. Neurosci. Res., 1997, 50, 937-945.
35. Jang, J.H.; Surh, Y.J. Beta-amyloid-induced apoptosis is associated with cyclooxygenase-2 up-regulation via the mitogen-activated protein kinase-NF-kappaB signaling pathway. Free Radic. Biol. Med., 2005, 38, 1604-1613.
36. Rao, P.; Knaus, E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J. Pharm. Pharm. Sci., 2008, 11, 81s-110s.
37. Oddo, S.; Caccamo, A.; Tseng, B.; Cheng, D.; Vasilevko, V.; Cribbs, D.H.; LaFerla, F.M. Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J. Neurosci., 2008, 28, 12163-12175.
38. MacKenzie, I.R.A.; Munoz, D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology, 1998, 50, 986-990.
39. Alafuzoff, I.; Overmyer, M.; Helisalmi, S.; Soininen, H. Lower counts of astroglia and activated microglia in patients with Alzheimer's disease with regular use of non-steroidal antiinflammatory drugs. J. Alzheimers Dis., 2000, 2, 37-46.
40. Breitner, J.C.S.; Wyse, B.W.; Anthony, J.C.; Welsh-Bohmer, K.A.; Steffens, D.C.; Norton, M.C.; Tschanz, J.T.; Plassman, B.L.; Meyer, M.R.; Skoog, I. APOE-epsilon 4 count predicts age when prevalence of AD increases, then declines - The Cache County Study. Neurology, 1999, 53, 321-331.
41. Breitner, J.C.S.; Welsh, K.A.; Helms, M.J.; Gaskell, P.C.; Gau, B.A.; Roses, A.D.; Vance, M.A.P.; Saunders, A.M. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging, 1995, 16, 523-530.
42. Zandi, P.P.; Anthony, J.C.; Hayden, K.M.; Mehta, K.; Mayer, L.; Breitner, J.C. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology, 2002, 59, 880-886.
43. in t' Veld, B.A.; Ruitenberg, A.; Hofman, A.; Launer, L.J.; van Duijn, C.M.; Stijnen, T.; Breteler, M.M.; Stricker, B.H. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med., 2001, 345, 1515-1521.
44. Aisen, P.S. The inflammatory hypothesis of Alzheimer disease: dead or alive? Alzheimer Dis. Assoc. Disord., 2008, 22, 4-5.
45. Hayden, K.M.; Zandi, P.P.; Khachaturian, A.S.; Szekely, C.A.; Fotuhi, M.; Norton, M.C.; Tschanz, J.T.; Pieper, C.F.; Corcoran, C.; Lyketsos, C.G.; Breitner, J.C.; Welsh-Bohmer, K.A.; Cache County Investigators. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study. Neurology, 2007, 69, 275-282.
46. Szekely, C.A.; Breitner, J.C.; Fitzpatrick, A.L.; Rea, T.D.; Psaty, B.M.; Kuller, L.H.; Zandi, P.P. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology, 2008, 70, 17-24.
47. Jack, C.R., Jr.; Knopman, D.S.; Jagust, W.J.; Shaw, L.M.; Aisen, P.S.; Weiner, M.W.; Petersen, R.C.; Trojanowski, J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol., 2010, 9, 119-128.
48. Varvel, N.H.; Bhaskar, K.; Kounnas, M.Z.; Wagner, S.L.; Yang, Y.; Lamb, B.T.; Herrup, K. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J. Clin. Invest., 2009, 119, 3692-3702.
49. Mori, T.; Koyama, N.; Arendash, G.W.; Horikoshi-Sakuraba, Y.; Tan, J.; Town, T. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia, 2010, 58, 300-314.
50. Price, J.L.; Morris, J.C. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol., 1999, 45, 358-368.
51. Rumble, B.; Retallack, R.; Hilbich, C.; Simms, G.; Multhaup, G.; Martins, R.; Hockey, A.; Montgomery, P.; Beyreuther, K.; Masters, C.L. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N. Engl. J. Med., 1989, 320, 1446-1452.
52. Hyman, B.T.; West, H.L.; Rebeck, G.W.; Lai, F.; Mann, D.M. Neuropathological changes in Down's syndrome hippocampal formation: effect of age on and apolipoprotein E genotype. Arch. Neurol., 1995, 52, 373-378.
53. Morris, J.C.; Storandt, M.; McKeel, D.W., Jr.; Rubin, E.H.; Price, J.L.; Grant, E.A.; Berg, L. Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology, 1996, 46, 707-719.
54. Rabinovici, G.D.; Jagust, W.J. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav. Neurol., 2009, 21, 117-128.
55. Fagan, A.M.; Roe, C.M.; Xiong, C.; Mintun, M.A.; Morris, J.C.; Holtzman, D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol., 2007, 64, 343-349.
56. Fagan, A.M.; Mintun, M.A.; Shah, A.R.; Aldea, P.; Roe, C.M.; Mach, R.H.; Marcus, D.; Morris, J.C.; Holtzman, D.M. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol. Med., 2009, 1, 371-380.
57. Scheff, S.W.; Price, D.A.; Schmitt, F.A.; DeKosky, S.T.; Mufson, E.J. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology, 2007, 68, 1501-1508.
58. Liang, W.S.; Dunckley, T.; Beach, T.G.; Grover, A.; Mastroeni, D.; Ramsey, K.; Caselli, R.J.; Kukull, W.A.; McKeel, D.; Morris, J.C.; Hulette, C.M.; Schmechel, D.; Reiman, E.M.; Rogers, J.; Stephan, D.A. Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology. Neurobiol. Aging, 2010, 31(4), 549-566.
59. Sze, C.I.; Bi, H.K.-D.B.K.; Filley, C.M.; Martin, L.J. N-Methyl-Dasparate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer's disease. J. Neurol. Sci., 2001, 182, 151-159.
60. Harigaya, Y.; Shoji, M.; Shirao, T.; Hirai, S. Disappearance of actin-binding protein, drebrin, from hippocampal synapses in Alzheimer's Disease. J. Neurosci. Res., 1996, 43, 87-92.
61. Counts, S.E.; Nadeem, M.; Lad, S.P.; Wuu, J.; Mufson, E.J. Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment. J. Neuropathol. Exp. Neurol., 2006, 65, 592-601.
62. Aoki, C.; Sekino, Y.; Hanamura, K.; Fujisawa, S.; Mahadomrongkul, V.; Ren, Y.; Shirao, T. Drebrin A is a postsynaptic protein that localizes in vivo to the submembranous surface of dendritic sites forming excitatory synapses. J. Comp. Neurol., 2005, 483, 383-402.
63. Lahiri, D.K.; Nall, C. Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and interleukin-1. Mol. Brain Res., 1995, 32, 233-240.
64. Sastre, M.; Dewachter, I.; Landreth, G.E.; Willson, T.M.; Klockgether, T.; van Leuven, F.; Heneka, M.T. Nonsteroidal antiinflammatory drugs and peroxisome proliferator-activated receptorgamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci., 2003, 23, 9796-9804.
65. Nilsson, L.N.; Bales, K.R.; DiCarlo, G.; Gordon, M.N.; Morgan, D.; Paul, S.M.; Potter, H. Alpha-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J. Neurosci., 2001, 21, 1444-1451.
66. Koenigsknecht-Talboo, J.; Landreth, G.E. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci., 2005, 25, 8240-8249.
67. Shie, F.S.; Montine, K.S.; Breyer, R.M.; Montine, T.J. Microglial EP2 as a new target to increase amyloid beta phagocytosis and decrease amyloid beta-induced damage to neurons. Brain Pathol., 2005, 15, 134-138.
68. Wyss-Coray, T.; Mucke, L. Inflammation in neurodegenerative disease--a double-edged sword. Neuron, 2002, 35, 419-432.
69. Wyss-Coray, T.; Loike, J.D.; Brionne, T.C.; Lu, E.; Anankov, R.; Yan, F.; Silverstein, S.C.; Husemann, J. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med., 2003, 9, 453-457.
70. Stalder, M.; Deller, T.; Staufenbiel, M.; Jucker, M. 3DReconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol. Aging, 2001, 22, 427-434.
71. Frackowiak, J.; Wisniewski, H.M.; Wegiel, J.; Merz, G.S.; Iqbal, K.; Wang, K.C. Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol. (Berl), 1992, 84, 225-233.
72. D'Andrea, M.R.; Cole, G.M.; Ard, M.D. The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol. Aging, 2004, 25, 675-683.
73. Bard, F.; Cannon, C.; Barbour, R.; Burke, R.; Games, D.; Grajeda, H.; Guido, T.; Hu, K.; Huang, J.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, M.; Lieberburg, I.; Motter, R.; Nguyen, M.; Soriano, F.; Vasquez, N.; Weiss, K.; Welch, B.; Seubert, P.; Schenk, D.; Yednock, T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med., 2000, 6, 916-919.
74. Bard, F.; Barbour, R.; Cannon, C.; Carretto, R.; Fox, M.; Games, D.; Guido, T.; Hoenow, K.; Hu, K.; Johnson-Wood, K.; Khan, K.; Kholodenko, D.; Lee, C.; Lee, M.; Motter, R.; Nguyen, M.; Reed, A.; Schenk, D.; Tang, P.; Vasquez, N.; Seubert, P.; Yednock, T. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc. Natl. Acad. Sci. USA, 2003, 100, 2023-2028.
75. Butovsky, O.; Koronyo-Hamaoui, M.; Kunis, G.; Ophir, E.; Landa, G.; Cohen, H.; Schwartz, M. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc. Natl. Acad. Sci. USA, 2006, 103, 11784-11789.
76. El Khoury, J.; Luster, A.D. Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol. Sci., 2008, 29, 626-632.
77. Jiang, Q.; Lee, C.Y.; Mandrekar, S.; Wilkinson, B.; Cramer, P.; Zelcer, N.; Mann, K.; Lamb, B.; Willson, T.M.; Collins, J.L.; Richardson, J.C.; Smith, J.D.; Comery, T.A.; Riddell, D.; Holtzman, D.M.; Tontonoz, P.; Landreth, G.E. ApoE promotes the proteolytic degradation of Abeta. Neuron, 2008, 58, 681-693.
78. Frautschy, S.A.; Yang, F.; Calderón, L.; Cole, G.M. Rodent models of Alzheimer's disease: rat Aβ infusion approaches to amyloid deposits. Neurobiol. Aging, 1996, 17, 311-321.
79. Town, T.; Laouar, Y.; Pittenger, C.; Mori, T.; Szekely, C.A.; Tan, J.; Duman, R.S.; Flavell, R.A. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med., 2008, 14, 681-687.
80. Yip, A.G.; Green, R.C.; Huyck, M.; Cupples, L.A.; Farrer, L.A. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr., 2005, 5, 2.
81. Jofre-Monseny, L.; Minihane, A.M.; Rimbach, G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol. Nutr. Food Res., 2008, 52, 131-145.
82. Licastro, F.; Mallory, M.; Hansen, L.A.; Masliah, E. Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. J. Neuroimmunol., 1998, 88, 105-110.
83. Engelhart, M.J.; Geerlings, M.I.; Meijer, J.; Kiliaan, A.; Ruitenberg, A.; van Swieten, J.C.; Stijnen, T.; Hofman, A.; Witteman, J.C.; Breteler, M.M. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch. Neurol., 2004, 61, 668-672.
84. Fotuhi, M.; Zandi, P.P.; Hayden, K.M.; Khachaturian, A.S.; Szekely, C.A.; Wengreen, H.; Munger, R.G.; Norton, M.C.; Tschanz, J.T.; Lyketsos, C.G.; Breitner, J.C.; Welsh-Bohmer, K. Better cognitive performance in elderly taking antioxidant vitamins E and C supplements in combination with nonsteroidal antiinflammatory drugs: the Cache County Study. Alzheimers Dement., 2008, 4, 223-227.
85. In'T Veld, B.A.; Launer, L.J.; Hoes, A.W.; Ott, A.; Hofman, A.; Breteler, M.M.; Stricker, B.H. NSAIDs and incident Alzheimer's Disease. The Rotterdam study. Neurobiol. Aging, 1998, 19, 607-611.
86. Breitner, J.C.; Haneuse, S.J.; Walker, R.; Dublin, S.; Crane, P.K.; Gray, S.L.; Larson, E.B. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology, 2009, 72, 1899-1905.
87. Arvanitakis, Z.; Grodstein, F.; Bienias, J.L.; Schneider, J.A.; Wilson, R.S.; Kelly, J.F.; Evans, D.A.; Bennett, D.A. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology, 2008, 70, 2219-2225.
88. Pasqualetti, P.; Bonomini, C.; Dal Forno, G.; Paulon, L.; Sinforiani, E.; Marra, C.; Zanetti, O.; Rossini, P.M. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging Clin. Exp. Res., 2009, 21, 102-110.
89. Calon, F.; Lim, G.P.; Yang, F.; Morihara, T.; Teter, B.; Ubeda, O.; Rostaing, P.; Triller, A.; Salem, N., Jr.; Ashe, K.H.; Frautschy, S.A.; Cole, G.M. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron, 2004, 43, 633-645.
90. Calon, F.; Lim, G.P.; Morihara, T.; Yang, F.; Ubeda, O.; Salem, N.J.; Frautschy, S.A.; G.M.C. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur. J. Neurosci., 2005, 22, 617-626.
91. Lim, G.P.; Calon, F.; Morihara, T.; Yang, F.; Teter, B.; Ubeda, O.; Salem, N., Jr.; Frautschy, S.A.; Cole, G.M. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci., 2005, 25, 3032-3040.
92. Cole, G.M.; Ma, Q.L.; Frautschy, S.A. Omega-3 fatty acids and dementia. Prostaglandins Leukot. Essent. Fatty Acids, 2009, 81, 213-221.
93. Freund-Levi, Y.; Eriksdotter-Jonhagen, M.; Cederholm, T.; Basun, H.; Faxen-Irving, G.; Garlind, A.; Vedin, I.; Vessby, B.; Wahlund, L.O.; Palmblad, J. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol., 2006, 63, 1402-1408.
94. Freund-Levi, Y.; Hjorth, E.; Lindberg, C.; Cederholm, T.; Faxen-Irving, G.; Vedin, I.; Palmblad, J.; Wahlund, L.O.; Schultzberg, M.; Basun, H.; Eriksdotter, J.M. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study. Dement. Geriatr. Cogn. Disord., 2009, 27, 481-490.
95. Lim, G.P.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S.A.; Cole, G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci., 2001, 21, 8370-8377.
96. Yang, F.; Lim, G.P.; Begum, A.N.; Ubeda, O.J.; Simmons, M.R.; Ambegaokar, S.S.; Chen, P.P.; Kayed, R.; Glabe, C.G.; Frautschy, S.A.; Cole, G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem., 2005, 280, 5892-5901.
97. Cole, G.M.; Teter, B.; Frautschy, S.A. Neuroprotective effects of curcumin. Adv. Exp. Med. Biol., 2007, 595, 197-212.
98. Begum, A.N.; Jones, M.R.; Lim, G.P.; Morihara, T.; Kim, P.; Heath, D.D.; Rock, C.L.; Pruitt, M.A.; Yang, F.; Hudspeth, B.; Hu, S.; Faull, K.F.; Teter, B.; Cole, G.M.; Frautschy, S.A. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. JPET 2008, 326, 196-208.